

July 03, 2020

## Narayana Hrudayalaya Limited: Ratings outstanding at [ICRA]AA- (Stable)/[ICRA]A1+

### Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long Term- Term Loan	565.00	565.00	[ICRA]AA- (Stable); Outstanding
Short Term- Non-fund Based	35.00	35.00	[ICRA]A1+; Outstanding
Long Term/ Short Term- Unallocated	45.00	45.00	[ICRA]AA- (Stable)/[ICRA]A1+; Outstanding
Long Term/ Short Term- Working Capital Non-Fund Based- Working Capital (sublimit)#	80.00 (40.00)	80.00 (40.00)	[ICRA]AA- (Stable)/[ICRA]A1+; Outstanding
Commercial Paper Programme	50.00	50.00	[ICRA]A1+; Outstanding
<b>Total</b>	<b>775.00</b>	<b>775.00</b>	

\*Instrument details are provided in Annexure-1

# Sub-limit of Long Term/ Short Term- Working Capital

### Rationale

The rating update follows the impact of the ongoing Covid-19 pandemic on the operational and financial profile of Narayana Hrudayalaya Limited (NH Group). Following the implementation of the nation-wide lockdown from March 24, 2020, the occupancy at NH Group's units have been adversely impacted. Notwithstanding the gradual lifting of restrictions, occupancy continues to remain subdued due to various factors including deferral of elective procedures, restrictions on travel, etc. The company operated at around 35% of its pre-Covid revenue run-rate for the month of April 2020. While the revenue rate has subsequently increased progressively in May and June, continued growth in Covid-19 cases across the country and consequent steps taken by state governments to reserve bed capacity for Covid-19 patients and cap prices may act as a constraint in the near term.

The high fixed costs and operating leverage associated with the company's business model is likely to result in losses at the OPBITDA level during Q1FY2021 with the consolidated OPBITDA break-even being around 70% of its pre-Covid revenue at the current cost structure post implementation of measures like graded cuts in compensation of its staff. However, ICRA notes that the company has a healthy liquidity profile (opening cash and liquid investments of Rs 172 crore for the year) which along with various cash conservation measures adopted will keep the reliance on additional borrowings limited. Notwithstanding the lower accruals in the current year, the company has no large capital expenditure plans and limited term debt repayments. Moreover, the company has strong financial flexibility on account of its established operational profile and moderate leverage. These factors support the credit profile of the company.

Due to the evolving nature of the pandemic, ICRA will continue to monitor the developments in the sector, including additional regulatory measures, if any, and update its assessment of the impact on NH Group's credit profile.

The previous detailed rating rationale is available on the following link: [Click here](#)

## Key rating drivers and their description

### Credit strengths

**Significant brand equity of Narayana Health brand** - The company enjoys a strong market position in the healthcare services industry and has an established brand equity, especially in the cardiac segment. Its goodwill and strong brand equity among patients and healthcare professionals has helped NHL in partnering with governmental bodies, not-for-profit trusts and charities, and private organisations to operate and manage their healthcare facilities. NHL targets to provide affordable healthcare which is evidenced by a lower Average Revenue Per Operating Bed (ARPOB) than most of its comparable peers.

**Spread across several geographies of India with strong presence in Karnataka and eastern India** - NHL has a network of 47 healthcare facilities, including 20 hospitals (multi-speciality and super-speciality healthcare facilities which provide tertiary care), one managed hospital, six heart centres (super-speciality units which are set up in a third-party hospital) and 19 primary care facilities (including clinics and information centres), across a total of over 30 cities, towns and villages in India, with 5,770 operational beds and the potential to reach a capacity of up to 6,579 beds. The company has an established presence and strong brand recognition in two geographical clusters, namely, Karnataka and eastern India, with an emerging presence in western, central and northern India. The company also has a global footprint with the establishment of Health City, Cayman Islands, North America.

**Strong presence in cardiac and renal sciences with continuing diversification into other specialties** - NHL has a good reputation and strong clinical capabilities in cardiac and renal sciences. It has been expanding its core specialty areas to include oncology, neurology and neurosurgery, orthopaedics and gastroenterology. The contribution of cardiac and renal sciences to inpatient revenue has reduced from 68% in FY2013 to 51% in 9M FY2020.

### Credit challenges

**Heavy reliance on top-three hospitals** - In FY2019 and 9MFY2020, the three flagship hospitals contributed significantly to the Group's revenues and EBITDA as several of the other hospitals were still ramping up. However, this dependence has moderated over the last couple of years. In 9mFY2020, 41% of the revenues and 74% of the EBITDA was contributed by the top three hospitals as against 42% and 84%, respectively in FY2019, partly due to the rising contribution from the Cayman Island hospital unit. Over the last three years, the company has commissioned new hospitals in Mumbai (in Q1FY2018) and Gurgaon (in Q4FY2018), apart from taking over Dharamashila Hospital (in Q1FY2018) and adding additional specialties. The losses in the new hospitals in growth phases have constrained the consolidated profit margins.

**Exposed to regulatory risks inherent in the sector**- Going forward, regulatory risks pertaining to restrictive pricing regulations levied by the Central and state government organisations could constrain the profit margins of the company. The ongoing Covid-19 pandemic may also cause disruption in NH's operations and remains a key event risk. Continued growth in Covid-19 cases across the country and consequent steps taken by state governments to reserve bed capacity for Covid-19 patients and cap prices may act as a constraint in the near term.

**Moderate leverage levels, albeit on a declining trend from peak levels in March 2018** - The debt levels of the company had increased to Rs 802 crore as on March 31, 2018 from Rs 217 crore as on March 31, 2017. The rise in debt was primarily on account of debt funded acquisition of partner's equity and consolidation of debt in the erstwhile associate entity viz. Health City Cayman Islands, and debt-funded acquisition of a new hospital in

Gurugram. However, the debt levels are currently on a declining trend, supported by gradual improvement in profitability and limited capital expenditure. The debt has reduced to Rs 677 crore as December 2019 from the peak level of Rs 802 crore as on March 2018. Leverage as measured by Debt / OPBITDA was 1.7 times and Adjusted Debt/ OPBITDA was 2.0 times as on December 31, 2019; moderated from the earlier elevated level of Debt / OPBITDA of 3.8 times and Adjusted Debt/ OPBITDA of 4.3 times as on March 31, 2018.

### Liquidity position: Adequate

The liquidity position of NHL is **adequate** backed by moderate debt repayment obligations as well as sanctioned working capital lines which are largely undrawn. Despite lower cash accruals in Q1 FY2021, the company has a healthy liquidity profile which along with various cash conservation measures adopted will keep the reliance on additional borrowings limited. As on March 2020, the group reported cash and liquid investments of Rs 172 crore.

### Rating sensitivities

**Positive triggers** – ICRA could upgrade NHL’s rating if there is an improvement in business risk profile through ramp-up in profitability in newer units resulting in reduced dependence on the flagship hospital units. Specific credit metrics which could lead to upgrade include Total Debt / OPBITDA less than 1.25 times on sustained basis.

**Negative triggers** – Negative pressure on NHL’s rating could arise if there is a weakening of the business risk profile through lower growth or profitability in the mature units or sustained delay in achieving profitability in the new units. Specific credit metrics which could lead to downgrade include Total Debt / OPBITDA higher than 2.5 times on sustained basis.

### Analytical approach

Analytical Approach	Comments
Applicable Rating Methodologies	<a href="#">Corporate Credit Rating Methodology</a> <a href="#">Rating Methodology for Hospitals</a>
Parent/Group Support	Not Applicable
Consolidation/Standalone	Consolidation: ICRA has consolidated NHL along with its operational subsidiaries and associate companies (mentioned in Annexure-2) on account of the strong business and financial linkages between these entities.

### About the company

NHL operates a chain of multispecialty, tertiary and primary healthcare facilities. Dr. Devi Shetty, who has over 30 years of medical experience, began NHL in 2000. The Group, which initially focused on cardiac and renal sciences, expanded to additional areas of focus such as cancer care, neurology and neurosurgery, orthopaedics, and gastroenterology and was rebranded as ‘Narayana Health’ in 2013 to reflect the diversified presence. The Group owns and operates certain hospitals apart from entering into management agreements with hospitals to acquire their operational control. NHL has a strong presence in the southern state of Karnataka and eastern India, with an emerging presence in western, central and northern India. NHL has a network of 47 healthcare facilities, including 20 hospitals (multi-speciality and super-speciality healthcare facilities which provide tertiary care), one managed hospital, six heart centres (super-speciality units which are set up in a third-party hospital) and 19 primary care facilities (including clinics and information centres), across a total of over 30 cities, towns and villages in India, with 5,770 operational beds and the potential to reach a capacity of up to 6,579 beds.

### Key financial indicators (audited)

	FY2018	FY2019	9mFY2020
Operating Income (Rs. crore)	2280.9	2860.9	2384.0
PAT (Rs. crore)	56.0	61.6	107.0
OPBDIT/OI (%)	9.3%	10.1%	12.2%
PAT/OI (%)	2.5%	2.2%	4.5%
Total Outside Liabilities/Tangible Net Worth (times)	1.4	1.4	N.A.
Total Debt/OPBDIT (times)	3.8	2.8	1.7
Total Adjusted Debt/OPBDIT (times)#	4.3	3.2	2.0
Interest Coverage (times)	4.5	4.0	N.A.

# Total Adjusted Debt includes liability for business acquisition of Rs 106 crore, Rs 102 crore and Rs. 99 crore as on March 2018, March 2019 and December 2019 respectively which has been treated as debt by ICRA  
N.A. – Not Available

**Status of non-cooperation with previous CRA: Not applicable**

**Any other information: None**

## Rating history for past three years

	Instrument	Current Rating (FY2021)			Rating History for the Past 3 Years					
		Type	Amount Rated	Amount Outstanding	Rating	FY2020		FY2019	FY2018	
					3-July-2020	27-Mar-2020	4-Jul-2019	22-Feb-2019	2-Jan-2018	23-Nov-2017
1	Term Loan	Long Term	565.0	381.0 <sup>^</sup>	[ICRA]AA- (Stable)	[ICRA]AA- (Stable)	[ICRA]AA- (Stable)	[ICRA]AA- (Stable)	[ICRA]AA- (Stable)	[ICRA]AA- (Stable)
2	Non-Fund Based	Short Term	35.0	-	[ICRA]A1+	[ICRA]A1+	[ICRA]A1+	[ICRA]A1+	[ICRA]A1+	[ICRA]A1+
3	Unallocated	Long/Short Term	45.0	-	[ICRA]AA- (Stable)/ [ICRA]A1+	[ICRA]AA- (Stable)/ [ICRA]A1+	[ICRA]AA- (Stable)/ [ICRA]A1+	-	-	-
4	Fund based/Non-fund based Working Capital	Long/Short Term	80.0	-	[ICRA]AA- (Stable)/ [ICRA]A1+	[ICRA]AA- (Stable)/ [ICRA]A1+	[ICRA]AA- (Stable)/ [ICRA]A1+	[ICRA]AA- (Stable)/ [ICRA]A1+	[ICRA]AA- (Stable)/ [ICRA]A1+	[ICRA]AA- (Stable)/ [ICRA]A1+
5	Non-fund based – working capital	Long/Short Term	(40.0) #	-	[ICRA]AA- (Stable)/ [ICRA]A1+	[ICRA]AA- (Stable)/ [ICRA]A1+	[ICRA]AA- (Stable)/ [ICRA]A1+	[ICRA]AA- (Stable)/ [ICRA]A1+	[ICRA]AA- (Stable)/ [ICRA]A1+	[ICRA]AA- (Stable)/ [ICRA]A1+
6	Commercial Paper	Short Term	50.0	0.0	[ICRA]A1+	[ICRA]A1+	[ICRA]A1+	[ICRA]A1+	[ICRA]A1+	[ICRA]A1+
7	Unallocated	Long Term	-	-	-	-	-	-	[ICRA]AA- (Stable)	[ICRA]AA- (Stable)
8	Unallocated	Short Term	-	-	-	-	-	-	-	-

Amount in Rs. Crore

<sup>^</sup>as on December 2019

# Sub-limit of Long Term/ Short Term- Working Capital Limit of Rs. 80 crore

## Complexity level of the rated instrument

ICRA has classified various instruments based on their complexity as "Simple", "Complex" and "Highly Complex". The classification of instruments according to their complexity levels is available on the website [click here](#)

## Annexure-1: Instrument details

ISIN No	Instrument Name	Date of Issuance / Sanction	Coupon Rate	Maturity Date	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Long Term- Term Loan	Jun-2017	NA	Mar-2029	565.00	[ICRA]AA- (Stable)
NA	Short Term- Non-fund Based	NA	NA	NA	35.00	[ICRA]A1+
NA	Long Term/ Short Term- Unallocated	NA	NA	NA	45.00	[ICRA]AA- (Stable) / [ICRA]A1+
NA	Long Term/ Short Term- Working Capital	NA	NA	NA	80.00	[ICRA]AA- (Stable) / [ICRA]A1+
NA	Non-Fund Based- Working Capital (sublimit)	NA	NA	NA	(40.00)	[ICRA]AA- (Stable) / [ICRA]A1+
NA	Proposed Commercial Paper Programme	NA	NA	NA	50.00	[ICRA]A1+

Source: Narayana Hrudayalaya Limited

## Annexure-2: List of entities considered for consolidated analysis

Company Name	Ownership	Consolidation Approach
Narayana Hrudayalaya Surgical Hospital Pvt Ltd	100%	Full Consolidation
Meridian Medical Research and Hospital Ltd	99.12%	Full Consolidation
Narayana Health Institutions Pvt Ltd	100%	Full Consolidation
Narayana Hospitals Pvt Ltd	100%	Full Consolidation
Narayana Institute for Advanced Research Pvt Ltd	100%	Full Consolidation
Narayana Vaishno Devi Speciality Hospitals Pvt Ltd	100%	Full Consolidation
Narayana Hrudayalaya Hospitals Malaysia Sdn Bhd	100%!	Full Consolidation
Narayana Cayman Holdings Ltd	100%	Full Consolidation
Health City Cayman Islands Ltd (HCCI)	100%*	Full Consolidation
NH Health Bangladesh private Limited	100%	Full Consolidation
Narayana Holdings Private Limited	100%	Full Consolidation
Trimedx India Pvt Ltd	10.00%	Equity Method
Cura Technologies Inc.	43.33%	Equity Method
ISO Healthcare	20.02%	Equity Method

! Narayana Hrudayalaya Hospitals Malaysia Sdn Bhd - Commenced Members' Voluntary winding up in 2017 as per the extant provisions of the Malaysian Company Law. The company stands dissolved on 27<sup>th</sup> March 2018

\* HCCI was previously 28.6% Associate; the company w.e.f. January 2018 has become a wholly owned subsidiary

## Analyst Contacts

### Shubham Jain

+91 124 4545 306

[shubhamj@icraindia.com](mailto:shubhamj@icraindia.com)

### Mathew Kurian Eranat

+91 80 4332 6415

[mathew.eranat@icraindia.com](mailto:mathew.eranat@icraindia.com)

### Ashirbad Rath

+91 80 4332 6416

[ashirbad.rath@icraindia.com](mailto:ashirbad.rath@icraindia.com)

## Relationship Contact

### Jayanta Chatterjee

+91 80 4332 6401

[jayantac@icraindia.com](mailto:jayantac@icraindia.com)

## MEDIA AND PUBLIC RELATIONS CONTACT

### Ms. Naznin Prodhani

Tel: +91 124 4545 860

[communications@icraindia.com](mailto:communications@icraindia.com)

## Helpline for business queries:

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

[info@icraindia.com](mailto:info@icraindia.com)

## About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit [www.icra.in](http://www.icra.in)

## ICRA Limited

### Corporate Office

Building No. 8, 2nd Floor, Tower A; DLF Cyber City, Phase II; Gurgaon 122 002

Tel: +91 124 4545300

Email: [info@icraindia.com](mailto:info@icraindia.com)

Website: [www.icra.in](http://www.icra.in)

### Registered Office

1105, Kailash Building, 11th Floor; 26 Kasturba Gandhi Marg; New Delhi 110001

Tel: +91 11 23357940-50

### Branches

Mumbai + (91 22) 24331046/53/62/74/86/87

Chennai + (91 44) 2434 0043/9659/8080, 2433 0724/ 3293/3294,

Kolkata + (91 33) 2287 8839 /2287 6617/ 2283 1411/ 2280 0008,

Bangalore + (91 80) 2559 7401/4049

Ahmedabad+ (91 79) 2658 4924/5049/2008

Hyderabad + (91 40) 2373 5061/7251

Pune + (91 20) 2556 0194/ 6606 9999

© Copyright, 2020 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website [www.icra.in](http://www.icra.in) or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents